Company Description
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally.
The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers.
This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies.
The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services.
The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services.
The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children’s Hospital Los Angeles across its contract development and manufacturing organization.
Additionally, it has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and development.
Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
| Country | United States |
| Founded | 1947 |
| IPO Date | Jun 23, 2000 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 19,700 |
| CEO | James Foster |
Contact Details
Address: 251 Ballardvale Street Wilmington, Massachusetts 01887 United States | |
| Phone | 781 222 6000 |
| Website | criver.com |
Stock Details
| Ticker Symbol | CRL |
| Exchange | NYSE |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001100682 |
| CUSIP Number | 159864107 |
| ISIN Number | US1598641074 |
| Employer ID | 06-1397316 |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| James C. Foster J.D. | Chairman, President and Chief Executive Officer |
| Birgit Girshick | Corporate Executive Vice President and Chief Operating Officer |
| Michael Gunnar Knell | Corporate Senior Vice President and Chief Accounting Officer |
| Joseph W. LaPlume J.D. | Corporate Executive Vice President of Corporate Development and Strategy |
| Victoria L. Creamer | Corporate Executive Vice President and Chief People Officer |
| Glenn G. Coleman CPA | Corporate Executive Vice President and Chief Financial Officer |
| Prof. Julie Frearson Ph.D. | Corporate Senior Vice President and Chief Scientific Officer |
| Mark Mintz | Corporate EVice President, Chief Information Officer and Global Shared Services |
| Todd Spencer | Corporate Vice President of Investor Relations |
| Kerry Dailey | Corporate Senior Vice President and Chief Legal Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 31, 2026 | ARS | Filing |
| Mar 31, 2026 | DEF 14A | Other definitive proxy statements |
| Mar 26, 2026 | SCHEDULE 13G/A | Filing |
| Feb 25, 2026 | 8-K | Current Report |
| Feb 18, 2026 | 8-K | Current Report |
| Feb 18, 2026 | 10-K | Annual Report |
| Feb 18, 2026 | 8-K | Current Report |
| Feb 12, 2026 | SCHEDULE 13G | Filing |
| Feb 10, 2026 | SCHEDULE 13G/A | Filing |
| Jan 13, 2026 | 8-K | Current Report |